Nexstim's NBS 6 received MDR certification for post-operative rehabilitation

Translation: Original published in Finnish on 02/20/2026 at 07:20 am EET

Nexstim announced on Thursday that it has received MDR certification in the EU for its NBS 6 system for post-operative rehabilitation. The certification enables the marketing and sale of the system in the EU for upper limb motor rehabilitation after brain tumor surgery. Customers can now use the system for both pre-operative mapping and patient rehabilitation when surgery has caused problems with upper limb functionality. The news supports our growth estimates and, in our view, increases the attractiveness of the system through the diversification of indications.

Certification supports customers who perform mapping

The new certification for the NBS 6 system concerns the treatment of upper limb motor deficits that have arisen or worsened as a result of brain tumor surgery. According to the company, Nexstim's technology is used in this context as an adjunct therapy in motor rehabilitation. The certification is based on a multi-center study conducted at several prominent neurosurgical units, which demonstrated that a combination of navigated rTMS therapy and physiotherapy improves post-operative recovery.

We believe that the new indication is a good addition to Nexstim's therapy area offering, even though its immediate commercial potential is more limited compared to, for example, depression treatment. We estimate that the user base consists mainly of diagnostic customers who use the NBS 6 system for pre-operative mapping and can now expand the use of the system. For new customers, we believe the certificate makes the system a more attractive acquisition due to the new indication.

NBS 6 platform flexibly adapts to mapping and therapy

NBS 6 is Nexstim’s latest generation of systems, whose modular design allows the system to be tailored to each customer’s needs. The system already has MDR certification for pre-operative mapping of motor and speech cortices, and for the treatment of depression and chronic neuropathic pain. We believe the new certification strengthens the position of the NBS 6 platform, particularly among customers performing pre-surgical mapping. We expect the certification to particularly support the development of distributor sales through Brainlab, as customers can be offered solutions for an increasing number of indications.